Table 4. Analyses of SNPs and possible association with peripheral neuropathy or paclitaxel dose reduction.

		Peripheral neuropathy			Paclitaxel dose reduction
		Univariate analysis	Multivariate analysesa,b		Univariate analysis	Multivariate analysisa,c
Genetic variant	Comparison	P value	Hazard ratio (95% CI)	P value	P value	Hazard ratio (95% CI)	P value
CYP2C8*3 (c.416G>A)	*3 carriers vs non-carriers	0.018	1.59 (1.01–2.52)	0.045	0.81
CYP3A4 c.522-191C>T	Dominant (TT+CT vs CC)	0.44			0.14
TUBB2A c.-101T>C	Additive	0.83			0.16	0.76 (0.53–1.10)	0.14
	Dominant (CC+TC vs TT)	0.66			0.10
	Recessive (CC vs TC+TT)	0.59			0.13
FGD4 c.2044-236G>A	Additive	0.62			0.10	1.38 (1.02–1.86)	0.036
	Dominant (AA+AG vs GG)	0.46			0.04
	Recessive (AA vs AG+GG)	0.39			0.18
EPHA5 c.2895G>A	Additive	0.77			0.28
	Dominant (AA+AG vs GG)	0.84			0.13
	Recessive (AA vs AG+GG)	0.48			0.27

P value was calculated from the Gehan–Breslow–Wilcoxon test. SNPs with P<0.10 were selected for the Cox proportional hazards analysis.

^aMultiplicative genetic model, hazard ratio per variant allele except for CYP2C8*3.

^bHazard ratio adjusted for age, body surface area, cumulative paclitaxel dose in tertiles.

^cHazard ratio adjusted for cumulative paclitaxel dose in tertiles.